Hemolytic disease of the fetus and newborn (HDFN) is the development of anemia, hyperbilirubinemia, and finally hydrops fetalis in the fetus when antibodies to antigens on the surface of erythrocytes are transferred from the placenta to the fetus. The most common cause is D-HDFN. K (KEL1) from the Kell blood group system is the most potent immunogenic antigen after D among all blood group antigens. K-HDFN occurs in 0.1-0.3% of pregnant women. It accounts for 10% of cases of antibody-mediated severe fetal anemia. We present a successful management of Kell alloimmunization in a pregnant woman who had 3 times pregnancy loss with hydrops fetalis due to K-HDFN and who was proven to have K-HDFN in the postnatal period in her last pregnancy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288690 | PMC |
| http://dx.doi.org/10.1155/2024/1929147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hemolytic disease of the fetus and newborn and Rhesus alloimmunization in Latin American countries: a scoping review.
BMC Pregnancy Childbirth
December 2024
Immunology LATAM, Janssen, Mendoza, Buenos Aires, CP (1428), 1259, Argentina.
Background: Hemolytic disease of the fetus and newborn (HDFN) is a condition due to maternal blood group antibodies targeting antigens in fetal red blood cells, with significant prenatal/perinatal morbidity and mortality. Severe HDFN cases are often associated with alloimmunization against Rhesus D (RhD) or Kell antigens. Information about HDFN epidemiology and treatment in Latin American countries is limited.
View Article and Find Full Text PDFBackground: The ABO, Rh, and Kell blood groups are the most immunogenic and clinically important blood antigens. These antigens can trigger strong immune responses after blood transfusions, leading to alloimmunization and post-hemolytic transfusion reactions. The aim of this study was to determine prevalence of ABO, Rh, and Kell blood group antigens at the Al-Qurayyat Regional Laboratory and Blood Bank Center, Al-Qurayyat region, Saudi Arabia.
View Article and Find Full Text PDFCongenital portosystemic shunts: experience of a tertiary Tunisian referral center.
AJOG Glob Rep
November 2024
Department of Emergency, Maternity and Neonatology Center of Tunis, University of Tunis El Manar Faculty of Medicine of Tunis, Tunis, Tunisia (Achour).
Congenital portosystemic shunt is a rare condition in which communications between the systemic venous circulation and the portal veins drain blood directly into the systemic circulation. Diagnosis may occur from the prenatal period to adulthood. Nevertheless, diagnosing and treating a congenital portosystemic shunt, particularly in the perinatal stage, remain challenging, as multiple complications can occur.
View Article and Find Full Text PDFRed blood cell alloimmunization in transfused patients with hereditary hemorrhagic telangiectasia: A single centre retrospective study.
Transfus Apher Sci
December 2024
Division of Hematology-Oncology, Department of Medicine, St. Michael's Hospital, Unity Health Toronto, 30 Bond Street, Toronto, ON M5B 1W8, Canada; Department of Laboratory Medicine, St. Michael's Hospital, Unity Health Toronto, 30 Bond Street, Toronto, ON, M5B 1W8 Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Cir, Toronto, ON, M5S 1A8, Canada. Electronic address:
Article Synopsis
Red blood cell extended antigen typing in Omani patients with sickle cell disease to enhance daily transfusion practice.
Immunohematology
September 2024
1Hemocentro Unicamp, Campinas, São Paulo, Brazil.
Article Synopsis
- Many Omani patients with sickle cell disease mainly receive red blood cell transfusions that only account for ABO and D blood types, making them at high risk for alloimmunization.
- The study aims to enhance transfusion compatibility by using molecular techniques to predict the extended antigen profiles across multiple blood group systems for Omani patients.
- Initial findings indicate that the most common blood type among the enrolled 38 patients is group O, highlighting significant differences in RBC phenotypes compared to SCD patients in other regions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!